Literature DB >> 24360889

The association between Factor V Leiden with the presence and severity of coronary artery disease.

Mohammadali Boroumand1, Leila Pourgholi2, Shayan Ziaee2, Maryam Sotoudeh Anvari1, Arash Jalali3, Hamidreza Goodarzynejad4.   

Abstract

OBJECTIVES: The presence of Factor V Leiden (FVL) is proposed to be associated with a higher risk for arterial thrombosis. The aim of this study was to examine a relationship between FVL with the presence and severity of angiographically determined coronary artery disease (CAD). DESIGN AND METHODS: In this case-control study, 1083 patients having angiographic evidence of atherosclerosis with ≥50% luminal stenosis in their epicardial coronary tree were compared with patients with no luminal stenosis (n=320) or with luminal stenosis <50% (n=191) at coronary angiography as reference group. The severity of CAD was determined by vessel score and also a semi-quantitative scoring system (Gensini score). The presence of Factor V polymorphisms was analyzed using polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP).
RESULTS: FVL was found to be independently associated with the occurrence of CAD (p=0.020). As compared to wild genotype, heterozygote or homozygote mutant genotypes were more likely associated with a trend towards more severe CAD (adjusted OR=1.85, 95% CI=1.26 to 2.72; p=0.002, and adjusted OR=3.70, 95% CI=1.71 to 8.00; p=0.001; respectively). In addition, the median and inter-quartile range for Gensini score were significantly different among the GG (27.8, 3 to 66.5), GA (53.5, 10 to 104.1), and AA (92.8, 48.1 to 125.9) genotypes (p<0.001).
CONCLUSIONS: Our results confirmed the hypothesis that FVL mutation is a significant determinant of CAD risk. Furthermore, we observed that FVL is independently associated with increasing CAD severity.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary angiography; Coronary artery disease; Factor V Leiden; G1691A variant

Mesh:

Substances:

Year:  2013        PMID: 24360889     DOI: 10.1016/j.clinbiochem.2013.12.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Thrombophilia with an onset symptom of intracranial venous thrombosis: A case report and review of the literature.

Authors:  Li Cui; Lijun Zhu; Yuting Wang; Wuqiong Zhang; Shaokuan Fang
Journal:  Exp Ther Med       Date:  2017-04-06       Impact factor: 2.447

2.  The rs5888 single nucleotide polymorphism in scavenger receptor class B type 1 (SCARB1) gene and the risk of premature coronary artery disease: a case-control study.

Authors:  Hamidreza Goodarzynejad; Mohammadali Boroumand; Mehrdad Behmanesh; Shayan Ziaee; Arash Jalali
Journal:  Lipids Health Dis       Date:  2016-01-12       Impact factor: 3.876

3.  Analyzing Gensini Score as a Semi-Continuous Outcome.

Authors:  Homa Kashani; Hojjat Zeraati; Kazem Mohammad; Hamidreza Goodarzynejad; Mahmood Mahmoudi; Saeed Sadeghian; Mohammadali Boroumand
Journal:  J Tehran Heart Cent       Date:  2016-04-13

4.  Association between the Hepatic Lipase Promoter Region Polymorphism (-514 C/T) and the Presence and Severity of Premature Coronary Artery Disease.

Authors:  Hamidreza Goodarzynejad; Mohammadali Boroumand; Mehrdad Behmanesh; Shayan Ziaee; Arash Jalali; Leyla Pourgholi
Journal:  J Tehran Heart Cent       Date:  2017-07

5.  Association of FV G1691A Polymorphism but not A4070G With Coronary Artery Disease.

Authors:  Ahmed Amara; Meriem Mrad; Aicha Sayeh; Abdeddayem Haggui; Dhaker Lahideb; Najiba Fekih-Mrissa; Habib Haouala; Brahim Nsiri
Journal:  Clin Appl Thromb Hemost       Date:  2017-11-27       Impact factor: 2.389

6.  Cholesteryl ester transfer protein gene polymorphism (I405V) and premature coronary artery disease in an Iranian population.

Authors:  Hamidreza Goodarzynejad; Mohammadali Boroumand; Mehrdad Behmanesh; Shayan Ziaee; Arash Jalali
Journal:  Bosn J Basic Med Sci       Date:  2016-01-14       Impact factor: 3.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.